EXTL2 and gastric cancer: Validation analysis by WB for total EphA 4 receptor amounts and phosphorylation at Tyr-602 revealed that abolishing the expression of EXTL2 in gastric cancer cells, which is concomitant with higher HS levels, resulted in increased levels of the total receptor with a statistically significant reduction on its activation (Fig. 5B).